First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

NCT05141149 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: PBP1510 (400mg/16mL)
DRUG: Gemcitabine (1000 mg/m^2)

Sponsor

Prestige Biopharma Limited